---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| 1H2026 | First half of 2026 |
| 1H2027 | First half of 2027 |
| 1Q2026 | First quarter of 2026 |
| 1Q2027 | First quarter of 2027 |
| 2Q26 | Second quarter of 2026 |
| AAAAI | American Academy of Allergy, Asthma & Immunology |
| AAE-C1-INH | Acquired angioedema due to C1 inhibitor deficiency |
| AAE-C1INH | Acquired angioedema due to C1 inhibitor deficiency |
| ACARE | Angioedema Centers of Reference and Excellence |
| ACE | Angiotensin-converting enzyme |
| ADL | Activities of daily living |
| ADR | Adverse drug reaction |
| AE | Adverse event |
| AE-BK | Bradykinin-mediated angioedema |
| AE-QoL | Angioedema Quality of Life Questionnaire |
| AHFS | American Hospital Formulary Service |
| AHRQ-HCUP | Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project |
| AMM | Autorisation de mise sur le marché (marketing authorization) |
| AMRA | Angioedema Symptom Rating Scale |
| AMRA-3 | Three-item Angioedema Symptom Rating Scale |
| AMRA-5 | Five-symptom composite Angioedema Symptom Rating Scale |
| ANGPT1 | Angiopoietin-1 gene |
| AOH | Angio-œdème héréditaire (hereditary angioedema) |
| AP | Asia-Pacific |
| API | Active pharmaceutical ingredient |
| ASMR | Amélioration du service médical rendu (improvement in medical benefit) |
| ASP | Average sales price |
| ATE | Arterial thromboembolism |
| AUC | Area under the plasma concentration-time curve |
| AUCinf | Area under the plasma concentration-time curve from time zero to infinity |
| AUClast | Area under the plasma concentration-time curve from time zero to the last quantifiable concentration |
| B2R | Bradykinin B2 receptor |
| BCRP | Breast cancer resistance protein |
| BDKRB2 | Bradykinin receptor B2 gene |
| BID | Twice daily |
| Big4 | Big Four (Department of Veterans Affairs, Department of Defense, Public Health Service, and Coast Guard) price |
| BK | Bradykinin |
| BK-AE | Bradykinin-mediated angioedema |
| Bk2R | Bradykinin B2 receptor |
| BMI | Body mass index |
| C-QTcF | Concentration-QTcF |
| C0.25h | Plasma concentration at 0.25 hours |
| C1-INH | C1 esterase inhibitor |
| C1-INH-HAE | Hereditary angioedema due to C1 inhibitor deficiency |
| C1-INH-SC | Subcutaneous C1 esterase inhibitor |
| C1INH | C1 esterase inhibitor |
| C1INH-HAE | Hereditary angioedema due to C1 inhibitor deficiency |
| C4 | Complement component 4 |
| CDMO | Contract development manufacturing organization |
| CFS | Cascade family screening |
| CI | Confidence interval |
| CL/F | Total apparent body clearance |
| Cmax | Maximum plasma concentration |
| CO | Cardiac output |
| CoAs | Caregivers of adult patients |
| CoPs | Caregivers of pediatric patients |
| CPN1 | Carboxypeptidase N subunit 1 gene |
| CPO | Commercial Packaging Organization |
| Ctrough | Trough plasma concentration |
| CV | Cardiovascular |
| CVAD | Central venous access device |
| CYP | Cytochrome P450 |
| DBP | Diastolic blood pressure |
| DES | Discrete event simulation |
| EA | Each |
| EAACI | European Academy of Allergy and Clinical Immunology |
| EAG | External Assessment Group |
| EAMS | Early Access to Medicines Scheme |
| EAP | Expanded Access Program |
| EC50 | Half-maximal effective concentration |
| EC85 | Concentration producing 85% of the maximal effect |
| ECG | Electrocardiogram |
| ED | Emergency department |
| EEA | European Economic Area |
| eGFR | Estimated glomerular filtration rate |
| EMA | European Medicines Agency |
| eMIT | Electronic market information tool |
| EoP | End of Progression |
| ePRO | Electronic patient-reported outcome |
| EQ-5D | EuroQol 5-Dimensions |
| EQ-5D-5L | EuroQol 5-Dimensions, 5-level version |
| ER | Emergency room |
| EU | European Union |
| EudraCT | European Union Drug Regulating Authorities Clinical Trials Database |
| EUR | Euro |
| F12 | Coagulation factor XII gene |
| FAERS | FDA Adverse Event Reporting System |
| FAS | Full analysis set |
| FCT | Film-coated tablet |
| FDA | Food and Drug Administration |
| FFP | Fresh frozen plasma |
| FP | Frozen plasma |
| FSS | Federal Supply Schedule |
| FXII | Coagulation factor XII |
| FXIIa | Activated coagulation factor XII |
| G-BA | Gemeinsamer Bundesausschuss (Federal Joint Committee) |
| GA‐NRS | General Anxiety Numeric Rating Scale |
| GDP | Gross domestic product |
| GLP | Good Laboratory Practice |
| GPCRs | G protein-coupled receptors |
| HA | Hereditary angioedema |
| HADS | Hospital Anxiety and Depression Scale |
| HAE | Hereditary angioedema |
| HAE-1 | Hereditary angioedema type 1 (C1 inhibitor deficiency) |
| HAE-1/2 | Hereditary angioedema type 1 or type 2 |
| HAE-1/2/3 | Hereditary angioedema type 1, type 2, or type 3 |
| HAE-2 | Hereditary angioedema type 2 (C1 inhibitor dysfunction) |
| HAE-ANGPT | Hereditary angioedema associated with an angiopoietin-1 gene variant |
| HAE-BOIS-Europe | Hereditary Angioedema Burden of Illness Study in Europe |
| HAE-C1-INH | Hereditary angioedema due to C1 inhibitor deficiency |
| HAE-C1INH | Hereditary angioedema due to C1 inhibitor deficiency |
| HAE-CPN | Hereditary angioedema associated with a carboxypeptidase N gene variant |
| HAE-CPN1 | Hereditary angioedema associated with a carboxypeptidase N subunit 1 gene variant |
| HAE-DAB2IP | Hereditary angioedema associated with a DAB2 interacting protein gene variant |
| HAE-FXII | Hereditary angioedema associated with a factor XII gene variant |
| HAE-HSST | Hereditary angioedema associated with a heparan sulfate-glucosamine 3-O-sulfotransferase 6 gene variant |
| HAE-KNG | Hereditary angioedema associated with a kininogen 1 gene variant |
| HAE-MYOF | Hereditary angioedema associated with a myoferlin gene variant |
| HAE-nC1-INH | Hereditary angioedema with normal C1 inhibitor |
| HAE-nC1INH | Hereditary angioedema with normal C1 inhibitor |
| HAE-nl-C1INH | Hereditary angioedema with normal C1 inhibitor |
| HAE-PD | Hereditary angioedema as the principal diagnosis |
| HAE-PLG | Hereditary angioedema associated with a plasminogen gene variant |
| HAE-UNK | Hereditary angioedema with normal C1 inhibitor of unknown cause |
| HAEA | Hereditary Angioedema Association |
| HAS | Haute Autorité de Santé (French National Authority for Health) |
| HCHF | High-calorie, high-fat |
| HCP | Healthcare professional |
| HCPCS | Healthcare Common Procedure Coding System |
| HCRU | Healthcare resource utilization |
| HDI-SF | Hamilton Depression Inventory-Short Form |
| hERG | Human ether-à-go-go-related gene |
| HIV | Human immunodeficiency virus |
| HK | Hong Kong |
| HR | Hazard ratio; heart rate |
| HRQoL | Health-related quality of life |
| HS3ST6 | Heparan sulfate-glucosamine 3-O-sulfotransferase 6 gene |
| ICD-9-CM | International Classification of Diseases, Ninth Revision, Clinical Modification |
| ICER | Institute for Clinical and Economic Review; incremental cost-effectiveness ratio |
| ICUR | Incremental cost-utility ratio |
| IND | Investigational New Drug |
| INJ | Injection |
| IP | Inpatient |
| IQR | Interquartile range |
| IR | Immediate release |
| IRT | Interactive response technology |
| ITC | Indirect treatment comparison |
| IU | International units |
| IV | Intravenous |
| Kb | Antagonist equilibrium dissociation constant |
| Ki | Inhibition constant |
| KKS | Kallikrein-kinin system |
| KNG1 | Kininogen 1 gene |
| LE | Laryngeal edema |
| LS | Least squares |
| LSM | Least squares mean |
| LTP | Long-term prophylaxis |
| MA | Massachusetts |
| MAA | Marketing authorization application |
| MAD | Multiple ascending dose |
| MAP | Mean arterial pressure |
| MID | Minimal important difference |
| mITT | Modified intention-to-treat |
| MMRM | Mixed model for repeated measures |
| MNAR | Missing not at random |
| MSCS | Mean Symptom Complex Severity |
| MYOF | Myoferlin gene |
| N/A | Not applicable |
| NA | North America; not available |
| NDA | New drug application |
| NDC | National Drug Code |
| NE | Not estimable |
| NEDS | Nationwide Emergency Department Sample |
| NICE | National Institute for Health and Care Excellence |
| NJ | New Jersey |
| NOAEL | No-observed-adverse-effect level |
| NRS | Numeric rating scale |
| OD | On-demand |
| ODT | On-demand treatment |
| OLE | Open-label extension |
| OMIM | Online Mendelian Inheritance in Man |
| OP/ED | Outpatient or emergency department |
| OR | Odds ratio |
| ORPHA | Orphanet |
| P-gp | P-glycoprotein |
| PD | Pharmacodynamics |
| pd-C1INH | Plasma-derived C1 inhibitor |
| pdC-1INH | Plasma-derived C1 inhibitor |
| pdC1-INH | Plasma-derived C1 inhibitor |
| pdC1INH | Plasma-derived C1 inhibitor |
| PDUFA | Prescription Drug User Fee Act |
| PF | Preservative-free |
| PFS | Prefilled syringe |
| PGI-C | Patient Global Impression of Change |
| PGI-S | Patient Global Impression of Severity |
| PIP | Paediatric investigation plan |
| PK | Pharmacokinetics |
| PK/PD | Pharmacokinetic/pharmacodynamic |
| PKa | Plasma kallikrein |
| PKK | Prekallikrein |
| PLC-C | Posttraumatic Stress Disorder Checklist, Civilian Version |
| PLG | Plasminogen gene |
| PLN | Polish złoty |
| PM | Paediatric investigation plan modification |
| PPPY | Per patient per year |
| PPY | Per patient-year |
| PRFs | Patient record forms |
| PRO | Patient-reported outcome |
| PTSD | Posttraumatic stress disorder |
| PVs | Prognostic variables |
| PWDR | Powder |
| QALY | Quality-adjusted life-year |
| QoL | Quality of life |
| QT | Electrocardiographic interval from the onset of the QRS complex to the end of the T wave |
| QTc | QT interval corrected for heart rate |
| QTcF | QT interval corrected for heart rate by the Fridericia formula |
| rC1-INH | Recombinant C1 inhibitor |
| RCT | Randomized controlled trial |
| rhC1-INH | Recombinant human C1 inhibitor |
| rhC1INH | Recombinant human C1 inhibitor |
| RoW | Rest of world |
| rrm | Repeated-measures correlation coefficient |
| RWE | Real-world evidence |
| s.c. | Subcutaneous |
| SAD | Single ascending dose |
| SAD-POM | Single ascending dose, proof of mechanism |
| SAEs | Serious adverse events |
| SBP | Systolic blood pressure |
| SC | Subcutaneous |
| SCM | Standard caloric meal |
| SD | Standard deviation |
| SDP | Solvent detergent-treated plasma |
| SE | Standard error |
| SERPING1 | Serpin family G member 1 gene (encodes C1 inhibitor) |
| SF-12 | 12-Item Short Form Health Survey |
| SF-36 | 36-Item Short Form Health Survey |
| SMR | Service médical rendu (medical benefit) |
| SOC | System organ class |
| SOL | Solution |
| t1/2 | Elimination half-life |
| TA | Tranexamic acid |
| TE | Thromboembolic |
| TEAE | Treatment-emergent adverse event |
| TEMs | Treatment effect modifiers |
| TEQ | Treatment Effect Questionnaire |
| TESAEs | Treatment-emergent serious adverse events |
| tmax | Time to maximum plasma concentration |
| TOS | Treatment Outcome Score |
| TQT | Thorough QT |
| TRAE | Treatment-related adverse event |
| TSQM | Treatment Satisfaction Questionnaire for Medication |
| TTCR | Time to complete resolution |
| TTO | Time trade-off |
| UK | United Kingdom |
| US | United States |
| USA | United States of America |
| VA | Department of Veterans Affairs |
| VAS | Visual analog scale |
| VAS-3 | Visual analog scale, 3-symptom composite |
| VAS-5 | Visual analog scale, 5-symptom composite |
| VAT | Value-added tax |
| VEGF | Vascular endothelial growth factor |
| VIL | Vial |
| VTE | Venous thromboembolism |
| WAC | Wholesale acquisition cost |
| WAO | World Allergy Organization |
| WHO | World Health Organization |
| WPAI-GH | Work Productivity and Activity Impairment-General Health questionnaire |
| XR | Extended release |

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
